We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00347841
First Posted: July 4, 2006
Last Update Posted: June 1, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Innovative Medical
  Purpose
To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.

Condition Intervention Phase
Glaucoma Drug: Bimatoprost 0.03%, Latanoprost Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

Resource links provided by NLM:


Further study details as provided by Innovative Medical:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • · Male or female > 18 years of age

    • Documented low-responder to latanoprost therapy as delineated in the outline above.
    • Diagnosis of open-angle glaucoma or ocular hypertension
    • Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria:

  • · Known contraindication to bimatoprost or any component of any study medication

    • Uncontrolled systemic disease
    • Active ocular disease other than glaucoma or ocular hypertension
    • Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
    • History of intraocular surgery within the last 3 months
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00347841


Locations
United States, Pennsylvania
Dr. Noecker
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: Robert Noecker, MD UPMC Eye Center
  More Information

ClinicalTrials.gov Identifier: NCT00347841     History of Changes
Other Study ID Numbers: 5178
First Submitted: June 30, 2006
First Posted: July 4, 2006
Last Update Posted: June 1, 2007
Last Verified: May 2007

Additional relevant MeSH terms:
Latanoprost
Bimatoprost
Antihypertensive Agents